Glucose-6-phosphate translocase as a target for the design of antidiabetic agents

Drugs of the Future

Volumn 26, Issue 7, 2001, Pages 687-693

  Parker, J C ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 NITROSALICYLALDEHYDE; ANTIDIABETIC AGENT; CARRIER PROTEIN; CHLOROGENIC ACID; ENZYME INHIBITOR; GLUCOSE 6 PHOSPHATASE; GLUCOSE 6 PHOSPHATE; ILICICOLINIC ACID B; KODIASTATIN A; OXODIPEROXO(1,10 PHENANTHROLIN)VANADATE; PHLORETIN; PYRIDOXAL 5 PHOSPHATE; S 3438; S 4048; TETRAHYDROTHIENYLPYRIDINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ACTIVITY; DRUG DESIGN; ENZYME ACTIVE SITE; ENZYME INHIBITION; HYPERGLYCEMIA; NONHUMAN; REVIEW;

EID: 0034765181     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2001.026.07.858712     Document Type: Review

References (61)

1. The growing burden of diabetes in the world population
2. Acarbose: Its role in the treatment of diabetes mellitus
3. Long-term efficacy and safety of acarbose in the treatment of obese subjects with noninsulin-dependent diabetes mellitus
4. Sufonylureas in NIDDM
5. Novel sulfonylurea and non-sulfonylurea drugs to promote the secretion of insulin
6. Effects of troglitazone and metformin on glucose and lipid metabolism
7. Recent developments in oral hypoglycemic agents
8. New therapeutic agents for the treatment of insulin resistance and NIDDM
9. Biguanides and NIDDM
10. Metformin
11. Mechanism by which metformin reduces glucose production in type 2 diabetes
12. Inhibition of hepatic gluconeogenesis by metformin
13. Fasting hyperglycemia in non-insulin dependent diabetes mellitus: Contributions of excessive hepatic glucose production and impaired tissue glucose uptake
14. Relationship between hepatic glucose production and fasting plasma glucose concentration in patients with NIDDM
15. 3H-glucose infusion
16. Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: A quantitative study
17. Hepatic gluconeogenic fluxes and glycogen turnover during fasting in humans. A stable isotope study
18. Quantifying the contribution of gluconeogenesis to glucose production in fasted human subjects using stable isotopes
19. 13C NMR
20. Quantitative contributions of gluconeogenesis to glucose production during fasting in type 2 diabetes mellitus
21. Blood glucose and the liver
22. Metabolic regulation by multifunctional glucose-6-phosphatase
23. Failure of substrate-induced gluconeogenesis to increase overall glucose appearance in normal humans. Demonstration of hepatic autoregulation without a change in plasma glucose concentration
24. The liver as a target for therapy in noninsulin dependent diabetes mellitus
25. Pharmacological interference with hepatic glucose production
26. Molecular pathology of glucose-6-phosphatase
27. Multi-functional glucose-6-phosphatase of the endoplasmic reticulum and nuclear membrane
28. The molecular basis of the hepatic microsomal glucose-6-phosphatase system
29. Phosphotransferase activities of kidney glucose-6-phosphatase
30. The microsomal glucose-6-phosphatase enzyme of pancreatic islets
31. Phosphohydrolase and phosphotransferase activities of intestinal glucose-6-phosphatase
32. Glucose-6-phosphatase structure, regulation, and function: An update
33. A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm
34. Peroxyvanadium compounds inhibit glucose-6-phosphatase activity and glucagon-stimulated hepatic glucose output in the rat in vivo
35. Vanadate inhibits liver fructose-2,6-bisphosphatase
36. Peroxovanadium compounds. A new class of potent phosphotyrosine phosphatase inhibitors which are insulin mimetics
37. Tungstate: A potent inhibitor of multifunctional glucose-6-phosphatase
38. Insulin-like actions of tungstate in diabetic rats: Normalization of hepatic glucose metabolism
39. Effects of tungstate in neonatally streptozotocin-induced diabetic rats: Mechanism leading to normalization of glycaemia
40. Effects of tungstate, a new potential oral anti-diabetic agent, in Zucker diabetic fatty rats
41. Identification of two new inhibitors of the hepatic glucose-6-phosphatase system
42. Glucose-6-phosphatase catalytic enzyme inhibitors: Synthesis and in vitro evaluation of novel 4,5,6,7-tetrahydrothienol[3,2-c]-and -[2,3-c]pyridines
43. The specificity of glucose-6-phosphatase of intact liver microsomes
44. Chlorogenic acid and hydroxynitrobenzaldehyde: New inhibitors of hepatic glucose-6-phosphatase
45. The inhibition of glucose-6-phosphatase by phlorizin and structurally-related compounds
46. Relationship between microsomal membrane permeability and the inhibition of hepatic glucose-6-phosphatase by pyridoxal phosphate
47. The requirement for membrane integrity in the inhibition of hepatic glucose-6-phosphatase by sulfhydryl agents and taurocholate
48. Evidence for the involvement of a glucose-6-phosphate carrier in microsomal glucose-6-phosphatase activity
49. Time-dependent inhibition of glucose-6-phosphatase by 3-mercaptopicolinic acid
50. Inhibition of the glucose-6-phosphatase system by N-bromoacetylethanolamine phosphate, a potential affinity label for auxiliary proteins
51. Inhibition of hepatic gluconeogenesis and glucose-6-phosphatase by aqueous extract of Bauhinia megalandra leaves
52. Kodaistatins, novel inhibitors of glucose-6-phosphalase translocase T1 from Aspergillus terreus Thom DSM 11247. Isolation and structural elucidation
53. Chlorogenic acid and synthetic chlorogenic acid derivatives: Novel inhibitors of hepatic glucose-6-phosphate translocase
54. Chlorogenic acid analogue S3483: A potent competitive inhibitor of the hepatic and renal glucose-6-phosphatase systems
55. New approaches to the treatment of diabetes
56. Pharmacodynamic profile of a novel inhibitor of the hepatic glucose-6-phosphatase system
57. Plasma glucose levels are reduced in rats and mice treated with an inhibitor of glucose-6-phosphate translocase
58. Alterations of carbohydrate and lipid intermediary metabolism during inhibition of glucose-6-phosphatase in rats
59. The role of glucose-6-phosphate in the control of glycogen synthase
60. Acute inhibition of glucose-6-phosphatase by S-4048 leads to increased de novo lipogenesis and development of fatty liver without affecting VLDL production in rats
61. Type lb glycogen storage disease is caused by a defect in the glucose-6-phosphatase translocase of the microsomal glucose-6-phosphatase system